Core Viewpoint - The Gross Law Firm is notifying shareholders of DexCom, Inc. about a class action lawsuit due to allegations of misleading statements and undisclosed material changes to their glucose monitoring products, which may have health implications for users [1][3]. Group 1: Allegations Against DexCom - The complaint alleges that DexCom made unauthorized design changes to its glucose monitoring products, the G6 and G7, which were not approved by the U.S. Food and Drug Administration [3]. - These design changes reportedly rendered the G6 and G7 devices less reliable, posing a material health risk to users who depend on them for accurate glucose readings [3]. - The enhancements claimed for the G7, including its reliability and accuracy, were allegedly overstated, and the company downplayed the severity of the issues related to the G7 devices [3]. Group 2: Legal and Financial Implications - The allegations suggest that DexCom is facing increased regulatory scrutiny and potential enforcement actions, which could lead to significant legal, reputational, and financial harm [3]. - The public statements made by DexCom were claimed to be materially false and misleading throughout the relevant period, which could impact investor confidence and stock performance [3]. Group 3: Class Action Participation - Shareholders who purchased shares of DXCM between January 8, 2024, and September 17, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff applications set for December 26, 2025 [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case's progress, with no cost or obligation to join [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its glucose monitoring products, the G6 and G7, which could pose health risks to users [1]. Group 1: Allegations - The complaint alleges that DexCom made unauthorized design changes to the G6 and G7 glucose monitoring products, which rendered them less reliable than previous versions [1]. - It is claimed that these changes presented a material health risk to users who depend on these devices for accurate glucose readings [1]. - The lawsuit asserts that the enhancements to the G7, including its reliability, accuracy, and functionality, were overstated by the defendants [1]. - The defendants allegedly downplayed the severity of the issues and health risks associated with the altered G7 devices [1]. - The allegations suggest that DexCom faced increased regulatory scrutiny and potential legal, reputational, and financial harm due to these issues [1]. - As a result, the public statements made by the defendants were deemed materially false and misleading throughout the relevant period [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as January 8, 2024, to September 17, 2025, and shareholders are encouraged to register for participation [1][2]. - The deadline for shareholders to seek lead plaintiff status is December 26, 2025, and there is no cost or obligation to participate in the case [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates on the case's progress [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [3].

Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed material changes to its glucose monitoring systems during the specified class period [1]. Group 1: Allegations Against DexCom - Defendants allegedly made false and misleading statements regarding unauthorized design changes to the G6 and G7 continuous glucose monitoring systems [3]. - The design changes reportedly rendered the G6 and G7 devices less reliable, posing health risks to users relying on accurate glucose readings [3]. - DexCom is accused of overstating the enhancements and reliability of the G7 device while downplaying the severity of issues related to adulterated devices [3]. - The company allegedly faced increased regulatory scrutiny and potential legal, reputational, and financial harm due to these issues [3]. Group 2: Legal Process and Representation - Investors in DexCom have until December 26, 2025, to seek appointment as lead plaintiffs in the class action [4]. - A lead plaintiff represents the interests of all class members and selects counsel to direct the litigation [4]. - Investors can choose to remain absent from the proceedings without affecting their ability to share in any recovery [4].

Core Insights - DexCom, Inc. (DXCM) has not met shareholder expectations in 2025, reflecting challenges within the broader medical equipment industry [1] Company Performance - The performance of DexCom, Inc. has been underwhelming for its shareholders in the current year [1] Industry Context - The medical equipment industry as a whole is facing difficulties, which may be impacting individual companies like DexCom [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on December 29, 2025 [1] Group 1: Class Action Details - Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To participate in the class action, investors can submit a form or contact the law firm for more information [3][6] - A lead plaintiff must file a motion with the court by December 29, 2025, to represent other class members in the litigation [3] Group 2: Case Background - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5] - Defendants are accused of overstating the enhancements and reliability of the G7 devices while downplaying the severity of the issues related to the adulterated devices [5] - The alleged misstatements and omissions have subjected DexCom to increased regulatory scrutiny and potential legal and financial repercussions [5] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company [4] - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4] - Founding partner Laurence Rosen has received recognition as a leading figure in the plaintiffs' bar, further establishing the firm's credibility [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities between July 26, 2024, and September 17, 2025, of the December 29, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought DexCom securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [2][5] - A lead plaintiff is a representative party who directs the litigation on behalf of other class members, and a motion must be filed by December 29, 2025, to serve in this role [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3] Group 3: Case Allegations - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [4] - It is claimed that the enhancements to the G7 were overstated, and the true scope of the issues was downplayed, leading to increased regulatory scrutiny and potential legal repercussions for DexCom [4] - The public statements made by DexCom during the Class Period are alleged to have been materially false and misleading, resulting in investor damages when the truth was revealed [4]

Core Viewpoint - A class action securities lawsuit has been filed against DexCom, Inc. for alleged securities fraud affecting investors between January 8, 2024, and September 17, 2025 [1] Group 1: Allegations of Fraud - The lawsuit claims that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, without FDA approval [2] - These design changes allegedly rendered the G6 and G7 less reliable, posing a material health risk to users who depend on these devices for accurate glucose readings [2] - The enhancements claimed for the G7, including its reliability, accuracy, and functionality, were reportedly overstated by the defendants [2] - The true scope and severity of the issues and health risks associated with the G7 devices were allegedly downplayed by the defendants [2] - The situation has subjected DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [2] - Public statements made by the defendants were claimed to be materially false and misleading throughout the relevant period [2] Group 2: Legal Process and Participation - Investors who suffered losses in DexCom during the specified timeframe have until December 26, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. regarding a class action lawsuit alleging that the company made misleading statements about its glucose monitoring products, the G6 and G7, which may have health risks for users [1][3]. Group 1: Allegations Against DexCom - The complaint alleges that DexCom made unauthorized design changes to the G6 and G7 glucose monitoring products, which were not approved by the U.S. Food and Drug Administration [3]. - These design changes reportedly made the G6 and G7 less reliable than previous versions, posing a material health risk to users who depend on these devices for accurate glucose readings [3]. - The enhancements claimed for the G7, including its reliability, accuracy, and functionality, were allegedly overstated by the defendants [3]. - The true scope and severity of the issues and health risks associated with the altered G7 devices were downplayed by the defendants [3]. - As a result of these actions, DexCom faced increased risks of regulatory scrutiny and potential legal, reputational, and financial harm [3]. - The public statements made by the defendants were claimed to be materially false and misleading throughout the relevant period [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as January 8, 2024, to September 17, 2025 [3]. - Shareholders are encouraged to register for the class action by December 26, 2025, to be eligible for potential recovery [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [5]. - The firm aims to ensure that companies engage in responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities between July 26, 2024, and September 17, 2025, of the December 29, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought DexCom securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1] - To join the class action, investors can visit the provided link or contact Phillip Kim, Esq. for more information [2][5] - A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation, and interested parties must file their motion by December 29, 2025 [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3] Group 3: Case Allegations - The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 continuous glucose monitoring systems, which rendered them less reliable and posed health risks to users [4] - Defendants allegedly overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues and health risks associated with them [4] - The allegations suggest that these misrepresentations subjected DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [4]

Core Points - Class actions have been initiated on behalf of stockholders of DexCom, Inc. and CarMax, Inc. with specific deadlines for investors to petition the court to serve as lead plaintiff [1] DexCom, Inc. (NASDAQ:DXCM) - The class period for DexCom is from January 8, 2024, to September 17, 2025, with a lead plaintiff deadline of December 26, 2025 [6] - The complaint alleges that DexCom made materially false and misleading statements regarding its business and compliance policies, including unauthorized design changes to the G6 and G7 devices that compromised their reliability and posed health risks to users [6] - The lawsuit claims that these misstatements subjected DexCom to increased regulatory scrutiny and potential legal and financial harm [6] CarMax, Inc. (NYSE:KMX) - The class period for CarMax is from June 20, 2025, to September 24, 2025, with a lead plaintiff deadline of January 2, 2026 [6] - The lawsuit alleges that CarMax's defendants overstated growth prospects, attributing earlier growth to temporary factors related to customer behavior influenced by tariff speculation [6] - As a result, the statements made by CarMax's defendants regarding the company's business and operations were deemed materially false and misleading [6]